An Iranian pharmaceutical company producing diabetes drugs under a license from a Canadian company has rejected claims it should recall its medication from the market because of high levels of a possible cancer-causing impurity, saying patients can use the drugs freely.
The Rasta Imen Daroo, a company representing Canada’s Apotex Corp in Iran, said in a Sunday statement that metformin tablets planned to be supplied by the company to the Iranian market are free carcinogen N-nitrosodimethylamine (NDMA).
The statement came after the US Food and Drug Administration (FDA) recommended that Apotex and one of its firms recall their metformin tablets because they have high levels of NDMA.
However, Rasta Imen Daroo said tablets it is planning to produce under Apotex license are not of the “extended release” type designated by the FDA as containing NDMA beyond acceptable levels.
It said the tablets are instead of the “immediate release” type endorsed by the FDA as safe, adding that diabetic patients could use the medication without any fear about the possible risks associated with the carcinogen.
Six major European countries announced on Friday that they would join a special trade exchange designed to alleviate the impact of the US sanctions on Iran. Belgium, Denmark, Finland,...
China, Iran to forge closer ties due to common threat from United States, analysts say
French minister criticises US over ‘unanswered’ Iran attacks
Islam has the best argument in support of human rights: Judiciary chief
UN adopts eight resolutions in condemnation of Israeli crimes in Palestine
Trump’s maximum pressure policy on Iran has backfired and experts say it will fail
S. Korea’s exports of humanitarian goods to Iran effectively halted after U.S. sanctions
Copyright © 2013 Real Iran. powered by Wordpress.